Biotech Values

[DewDiligence]

MNTA 2011-2013 News Flow

[Deleted Court’s decision on Amphastar PI (already done).]


Lovenox

• 7-Nov-2011: MNTA’s 3Q11 financial results and CC, which will presumably provide additional color on matters relating to MNTA’s Lovenox franchise.

• 4-Feb-2013 (not a typo): Start of NVS/MNTA’s patent-infringement suit against Teva. (This suit is now much less consequential than MNTA’s suit against Amphastar.)


Copaxone

• Late 2011/early 2012: Court ruling on Copaxone patent trial.

• Timing uncertain: FDA action on Copaxone ANDA.


Other programs

• Timing uncertain: Announcements regarding MNTA’s FoB programs.

• 1Q12: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.